Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)

NCT02526420 is registered in ClinicalTrials.gov with Versartis Inc. as lead sponsor.

NCT NCT02526420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02526420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)
Lead sponsor
Versartis Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2015
Completion date
October 31, 2016
Enrollment
36 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

adult growth hormone deficiency